Monrovia's Xencor Reports Third Quarter Loss of $40.2 Million

Monrovia's Xencor, a clinical-stage biopharmaceutical company, reported a net third-quarter loss of $40.2 million, compared to a net loss of $12.6 million for the same period in 2020. For the nine months ended September 30, 2021, net income was $9.6 million, compared to a net loss of $55.6 million for the same period in 2020. The company's stock closed today down 1.67%. https://v.gd/oBhWPy

- Brad Haugaard